Literature DB >> 35024795

Vaccine Effectiveness Against Life-Threatening Influenza Illness in US Children.

Samantha M Olson1, Margaret M Newhams2, Natasha B Halasa3, Leora R Feldstein1, Tanya Novak2,4, Scott L Weiss5, Bria M Coates6, Jennifer E Schuster7, Adam J Schwarz8, Aline B Maddux9, Mark W Hall10, Ryan A Nofziger11, Heidi R Flori12, Shira J Gertz13, Michele Kong14, Ronald C Sanders15, Katherine Irby15, Janet R Hume16, Melissa L Cullimore17, Steven L Shein18, Neal J Thomas19, Laura S Stewart3, John R Barnes1, Manish M Patel1, Adrienne G Randolph2,4,20.   

Abstract

BACKGROUND: Predominance of 2 antigenically drifted influenza viruses during the 2019-2020 season offered an opportunity to assess vaccine effectiveness against life-threatening pediatric influenza disease from vaccine-mismatched viruses in the United States.
METHODS: We enrolled children aged <18 years admitted to the intensive care unit with acute respiratory infection across 17 hospitals. Respiratory specimens were tested using reverse-transcription polymerase chain reaction for influenza viruses and sequenced. Using a test-negative design, we estimated vaccine effectiveness comparing odds of vaccination in test-positive case patients vs test-negative controls, stratifying by age, virus type, and severity. Life-threating influenza included death or invasive mechanical ventilation, vasopressors, cardiopulmonary resuscitation, dialysis, or extracorporeal membrane oxygenation.
RESULTS: We enrolled 159 critically ill influenza case-patients (70% ≤8 years; 51% A/H1N1pdm09 and 25% B-Victoria viruses) and 132 controls (69% were aged ≤8 years). Among 56 sequenced A/H1N1pdm09 viruses, 29 (52%) were vaccine-mismatched (A/H1N1pdm09/5A+156K) and 23 (41%) were vaccine-matched (A/H1N1pdm09/5A+187A,189E). Among sequenced B-lineage viruses, majority (30 of 31) were vaccine-mismatched. Effectiveness against critical influenza was 63% (95% confidence interval [CI], 38% to 78%) and similar by age. Effectiveness was 75% (95% CI, 49% to 88%) against life-threatening influenza vs 57% (95% CI, 24% to 76%) against non-life-threating influenza. Effectiveness was 78% (95% CI, 41% to 92%) against matched A(H1N1)pdm09 viruses, 47% (95% CI, -21% to 77%) against mismatched A(H1N1)pdm09 viruses, and 75% (95% CI, 37% to 90%) against mismatched B-Victoria viruses.
CONCLUSIONS: During a season when vaccine-mismatched influenza viruses predominated, vaccination was associated with a reduced risk of critical and life-threatening influenza illness in children. Published by Oxford University Press for the Infectious Diseases Society of America 2022.

Entities:  

Keywords:  case control; influenza; pediatrics; severity; vaccination

Mesh:

Substances:

Year:  2022        PMID: 35024795     DOI: 10.1093/cid/ciab931

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   20.999


  5 in total

Review 1.  Influenza Viruses and Vaccines: The Role of Vaccine Effectiveness Studies for Evaluation of the Benefits of Influenza Vaccines.

Authors:  Claudia Maria Trombetta; Otfried Kistner; Emanuele Montomoli; Simonetta Viviani; Serena Marchi
Journal:  Vaccines (Basel)       Date:  2022-05-01

2.  Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants.

Authors:  Natasha B Halasa; Samantha M Olson; Mary A Staat; Margaret M Newhams; Ashley M Price; Pia S Pannaraj; Julie A Boom; Leila C Sahni; Kathleen Chiotos; Melissa A Cameron; Katherine E Bline; Charlotte V Hobbs; Aline B Maddux; Bria M Coates; Kelly N Michelson; Sabrina M Heidemann; Katherine Irby; Ryan A Nofziger; Elizabeth H Mack; Laura Smallcomb; Stephanie P Schwartz; Tracie C Walker; Shira J Gertz; Jennifer E Schuster; Satoshi Kamidani; Keiko M Tarquinio; Samina S Bhumbra; Mia Maamari; Janet R Hume; Hillary Crandall; Emily R Levy; Matt S Zinter; Tamara T Bradford; Heidi R Flori; Melissa L Cullimore; Michele Kong; Natalie Z Cvijanovich; Suzanne M Gilboa; Kara N Polen; Angela P Campbell; Adrienne G Randolph; Manish M Patel
Journal:  N Engl J Med       Date:  2022-06-22       Impact factor: 176.079

3.  Life-Threatening Complications of Influenza versus COVID-19 in U.S. Children.

Authors:  Natasha B Halasa; Andrew J Spieker; Cameron C Young; Samantha M Olson; Margaret M Newhams; Justin Z Amarin; Kristin L Moffitt; Mari M Nakamura; Emily R Levy; Vijaya L Soma; Rana Talj; Scott L Weiss; Julie C Fitzgerald; Elizabeth H Mack; Aline B Maddux; Jennifer E Schuster; Bria M Coates; Mark W Hall; Stephanie P Schwartz; Adam J Schwarz; Michele Kong; Philip C Spinella; Laura L Loftis; Gwenn E McLaughlin; Charlotte V Hobbs; Courtney M Rowan; Melania M Bembea; Ryan A Nofziger; Christopher J Babbitt; Cindy Bowens; Heidi R Flori; Shira J Gertz; Matt S Zinter; John S Giuliano; Janet R Hume; Natalie Z Cvijanovich; Aalok R Singh; Hillary A Crandall; Neal J Thomas; Melissa L Cullimore; Manish M Patel; Adrienne G Randolph
Journal:  Clin Infect Dis       Date:  2022-06-19       Impact factor: 20.999

Review 4.  Progress towards the Development of a Universal Influenza Vaccine.

Authors:  Wen-Chien Wang; Ekramy E Sayedahmed; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Viruses       Date:  2022-07-30       Impact factor: 5.818

5.  Interim Estimates of 2021-22 Seasonal Influenza Vaccine Effectiveness - United States, February 2022.

Authors:  Jessie R Chung; Sara S Kim; Rebecca J Kondor; Catherine Smith; Alicia P Budd; Sara Y Tartof; Ana Florea; H Keipp Talbot; Carlos G Grijalva; Karen J Wernli; C Hallie Phillips; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Michael Reis; Krissy Moehling Geffel; Mary Patricia Nowalk; Juliana DaSilva; Lisa M Keong; Thomas J Stark; John R Barnes; David E Wentworth; Lynnette Brammer; Erin Burns; Alicia M Fry; Manish M Patel; Brendan Flannery
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2022-03-11       Impact factor: 17.586

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.